USCF Midstream Energy Income Fund ETF (ARCA: UMI)

Latest News for USCF Midstream Energy Income Fund ETF (ARCA:UMI)

jim_cramer_shutterstock

REIT

Real Estate

While a double-digit dividend yield may appear enticing to income investors, it is crucial to exercise caution when approaching these ultra-high-yielding names.

Jim Cramer Says This 13% Yielding Stock Is A Trap — Here Are 3 Dividend Plays That Could Be More Reliable

USCF Midstream Energy Income Fund ETF

Umicore SA

News

Communications Workers Of America Union Says AT&T Workers Authorize Strike; CWA Members At AT&T West In District 9 Have Voted Overwhelmingly To Authorize A Strike, If Necessary

WIIM

TSLA

Tesla shares are trading higher on continued post-earnings strength.

<h3 class="wp-block-heading">House-Approved Marijuana Banking Bill Advances In Delaware Senate</h3>
<p>A <strong>measure</strong> that advanced through <strong>Delaware House </strong>and seeks to put into effect a law under which <strong>banks doing business with licensed marijuana businesses would be protected got the green light at the state Senate</strong> committee this week.</p>
<p>On Wednesday, the legislation from Rep. <strong>Ed Osienski</strong> (D) and Sen. <strong>Trey Paradee</strong> (D) advanced through the Senate Health &amp; Social Services Committee.</p>
<p>The synopsis of <a href="https://legis.delaware.gov/BillDetail?legislationId=141114"><strong>House Bill 355</strong></a> stipulates that the measure "clarifies that banks, credit unions, armored car services, and providers of accounting services are not subject to prosecution under Delaware law merely by providing lawful services to licensed businesses engaged in the production, distribution and sale of cannabis in Delaware."</p>
<h3 class="wp-block-heading">Schumer Says Marijuana Reform Needs To Be A Bipartisan Effort</h3>
<p>On a federal level, Senate Majority Leader <strong>Chuck Schumer</strong> (D-NY) listed a <strong>bipartisan marijuana banking bill as a priority in his chamber</strong>, <a href="https://www.marijuanamoment.net/senators-will-do-our-best-to-pass-marijuana-banking-bill-in-a-bipartisan-way-schumer-says/">reported</a> Marijuana Moment.</p>
<p>On Tuesday he said "trying to deal with" the <strong>Secure and Fair Enforcement Regulation (SAFER) Banking Act </strong>"and cannabis reform," is on the Senate's agenda. He was asked about what's next for the chamber's members following this week's passage of a foreign aid package.</p>
<p>"We've got a lot to do," Schumer said referring to "a bunch of different bills". He added that lawmakers need to "work in a bipartisan way," while doing "our best to get many of them done."</p>
<h3 class="wp-block-heading">Georgia's Restrictive Hemp Measure Awaits Gov. Kemp's Approval</h3>
<p>Georgia Gov. <strong>Brian Kemp </strong>has until May 7 to weigh in on a bill that seeks to further regulate and license the purchase of<strong> hemp products to those 21 and older.</strong></p>
<p>Dubbed <strong>"</strong>The Georgia Hemp Farming Act," the bill from Republican Moultrie Sen. <strong>Sam Watson </strong>would mandate testing for all hemp-derived products, including CBD and Delta-8 edibles and drinks while prohibiting sales to minors.</p>
<p>Watson, whose legislation was approved by the state Senate late in the session, says his efforts are toward providing more protection for consumers, <a href="https://georgiarecorder.com/2024/04/23/bill-to-regulate-hemp-products-in-georgia-awaits-governors-signature-while-some-hope-for-veto/">reported</a> Georgia Recorder.</p>
<p>"We regulate tobacco, we regulate alcohol, we regulate food, yet we've got a ton of these products out there now that we're not regulating as a state to protect the people of our state," he said.&nbsp;"Kids go into these gas stations and buy gas and this stuff is being sold and nobody knows what's in it and nobody's checking it and that's just scary."</p>
<h3 class="wp-block-heading">Louisiana Bill To Create Regulatory Framework For Legal Marijuana Advances Through Legislature</h3>
<p>Meanwhile, in <strong>Louisiana,</strong> state House committee members gave the green light to a measure that would set up a <strong>regulatory framework for marijuana legalization,</strong> <a href="https://www.marijuanamoment.net/louisiana-lawmakers-approve-bill-to-create-marijuana-legalization-regulatory-framework/">reported</a> Marijuana Moment.</p>
<p>The bill builds on <a href="https://www.benzinga.com/markets/cannabis/21/06/21576197/louisiana-governor-signs-marijuana-decriminalization-bill-into-law">legislation</a> that decriminalized small amounts of cannabis possession <a href="https://www.benzinga.com/markets/cannabis/21/08/22293351/marijuana-possession-no-longer-criminal-offense-in-louisiana-cannabis-decriminalization-bill-goe">for personal use statewide in 2021.</a></p>
<p>The measure from Rep. <strong>Edmond Jordan</strong> (D) was approved this week in the <strong>House Health and Welfare Committee </strong>in a unanimous vote.</p>
<p>This bill is a prerequisite for the passage of additional bills that would allow possession of cannabis and tax marijuana sales.</p>
<p>Under an adult-use cannabis program, those 21 and older would be allowed to purchase up to one ounce of cannabis daily and apply for a license to grow up to six plants for personal use, with a cap of 12 plants per household.</p>
<p><em>Now read: <a href="https://www.benzinga.com/markets/cannabis/23/06/32897422/louisiana-governor-signs-marijuana-expungement-legislation-into-law">Louisiana Governor Signs Marijuana Expungement Legislation Into Law</a></em></p>


Cannabis

Government

Regulations

Politics

Marijuana Reform On Fast Track In These States As Sen. Schumer Stresses The Need For A Bipartisan Effort

<p>Maxim Group  analyst Michael Diana   maintains Enova International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENVA#NYSE">ENVA</a>) with a Buy and raises the price target from $70 to $78.</p>


Price Target

Analyst Ratings

ENVA

Maxim Group Maintains Buy on Enova International, Raises Price Target to $78

<p>Macquarie  analyst Chad Beynon   maintains Hilton Worldwide Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>) with a Neutral and raises the price target from $192 to $205.</p>


Macquarie Maintains Neutral on Hilton Worldwide Holdings, Raises Price Target to $205

<p>Thursday,<strong>&nbsp;Labcorp</strong>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) reported first-quarter sales increased 4.6% to $3.18 billion, beating the consensus of $3.12 billion. Base Business grew 6.7%.</p>
<p>The increase was due to organic revenue of 2.3%, acquisitions, net of divestitures of 1.8%, and foreign&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/n38426008/labcorp-announces-2024-first-quarter-results" rel="noreferrer noopener">currency translation of 0.5%</a>.&nbsp;</p>
<p>The 2.3% increase in organic revenue was driven by a 4.2% increase in the company&#8217;s organic Base Business, partially offset by a (1.9%) decrease in COVID-19 PCR testing (COVID-19 Testing).&nbsp;</p>
<p>The adjusted operating income margin for the quarter was 14.3%, almost unchanged from 14.7% a year ago.</p>
<p>Diagnostics Laboratories revenue for the quarter was&nbsp;$2.48&nbsp;billion, an increase of 4.1%.</p>
<p>Total volume increased by 3.4% as acquisition volume, net of divestitures contributed 2.2%, while organic volume increased by 1.2%.&nbsp;</p>
<p>Organic volume was up due to a 2.6% increase in the Base Business, including the negative impact&nbsp;from adverse weather&nbsp;of approximately 1%.&nbsp;Price/mix was up 1.9%.</p>
<p>Biopharma Laboratory Services revenue reached $710.9 million, up 7.5% due to organic growth of 5.1% and foreign currency translation of 2.4%.</p>
<p><strong>Guidance:&nbsp;</strong>Labcorp expects 2024 adjusted EPS of $14.45-$15.35&nbsp;versus prior&nbsp;guidance&nbsp;of&nbsp;$14.30-$15.40&nbsp;and consensus of&nbsp;$14.82.</p>
<p>Labcorp&#8217;s&nbsp;2024 sales are expected to increase by 4.8%-6.4% compared to prior guidance of 4.7%-6.5%, Y/Y.</p>
<p>The guidance includes Diagnostics Laboratories sales growth guidance of 4.8%-6.0% and Biopharma Laboratory Services sales growth of 3.7%-5.7%, compared to prior guidance of 3.2%-4.8% and 5.5%-7.5%, respectively.</p>
<p>On&nbsp;Wednesday, the company said it will acquire bankrupt genetic test maker&nbsp;<strong>Invitae&nbsp;Corporation</strong>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/NVTA#OTC">NVTA</a>) for $239 million, a few months after the genetic test maker&nbsp;<a target="_blank" href="https://www.benzinga.com/news/24/02/36938401/softbank-backed-genetic-testing-invitaes-descent-from-7b-valuation-to-near-bankruptcy" rel="noreferrer noopener">filed for bankruptcy.</a></p>
<p>Labcorp expects this transaction would generate approximately $275 million-$300 million in annual revenue, with&nbsp;the majority in specialty testing areas such as&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/n38420784/labcorp-announces-winning-bid-for-select-assets-of-invitae" rel="noreferrer noopener">oncology and rare diseases</a>.</p>
<p><strong>William Blair&nbsp;</strong>suggests investors may seek clarification regarding the deal due to Invitae&#8217;s increased cash burn. If Invitae can control this, the acquisition could enhance its portfolio by utilizing Labcorp&#8217;s infrastructure, especially in oncology and rare diseases testing.&nbsp;</p>
<p>Labcorp&#8217;s aggressive M&amp;A approach, with over&nbsp;$475 million&nbsp;spent recently, may not significantly boost segment growth but could create long-term benefits by expanding solutions and customer reach in a changing market.</p>
<p><strong>Price Action:</strong> LH shares are down 4.7% at $197.86 at last check Thursday.</p>
<p><em>Now Read: <a href="https://www.benzinga.com/markets/equities/24/04/38436183/magnificent-7-tumble-wipe-out-300-billion-on-metas-weak-guidance-q1-stagflation-woes">Magnificent 7 Tumble, Wipe Out $300 Billion On Meta&#8217;s Weak Guidance, Q1 Stagflation Woes</a></em></p>
<p><em>Image generated using artificial intelligence via Midjourney.</em></p>


Analyst Color

Earnings

Large Cap

Guidance

Health Care

Movers

Trading Ideas

General

Laboratory Corporation Of America Holdings

NVTA

Labcorp's Q1 Revenue Surpasses Forecasts; Analysts Scrutinize Invitae Deal

<p><strong>Kaspa's</strong> (CRYPTO:KAS) price has decreased 3.84% over the past 24 hours to <strong>$0.12</strong>. This is contrary to the coins performance over the past week where it has experienced an up-trend of 3.0%, moving from $0.12 to its current price.</p>
<p>The chart below compares the price movement and volatility for Kaspa over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714071822_0.png" alt="price_chart" /></p>
<p>Kaspa's trading volume has climbed 38.0% over the past week along with the circulating supply of the coin, which has increased 0.59%. This brings the circulating supply to 23.09 billion, which makes up an estimated 80.44% of its max supply of 28.70 billion. According to our data, the current market cap ranking for KAS is #46 at $2.80 billion.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714071822_1.png" alt="supply_and_vol" /></p>
<p><a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

Cryptocurrency Kaspa Falls More Than 3% In 24 hours

<p>A coalition of 20 U.S. Democratic lawmakers sent a letter on Wednesday to the Drug Enforcement Administration (DEA) and Department of Justice, calling for the prompt removal of marijuana from Schedule I of the Controlled Substances Act (CSA).</p>
<p>Led by Sens. <strong>Elizabeth Warren </strong>(D-Mass.) and <strong>John Fetterman</strong> (D-Penn.), along with Reps. <strong>Earl Blumenauer</strong> (D-Ore.) and <strong>Barbara Lee</strong> (D-Calif.), the letter stressed the urgency of the matter, telling DEA Administrator <strong>Anne Milgram</strong> and Attorney General <strong>Merrick Garland</strong> that it's been eight months since the Department of Health and Human Services (HHS) <a href="https://www.benzinga.com/markets/cannabis/23/08/34120876/health-officials-to-dea-ease-federal-restrictions-on-cannabis-will-this-set-stage-for-legalizati">recommended the DEA reclassify cannabis</a> from Schedule I to Schedule III a year-and-a-half since President Joe Biden <a href="https://www.benzinga.com/markets/cannabis/22/10/29204539/biden-wants-to-see-marijuana-scheduling-review-as-quickly-as-possible-hhs-top-official-says">ordered a review of marijuana's classification</a>.</p>
<p>"It is time for the Drug Enforcement Administration (DEA) to act," the lawmakers <a href="https://www.warren.senate.gov/imo/media/doc/2024.04.24%20Follow-up%20letter%20to%20DEA%20on%20marijuana.pdf">wrote in the letter</a>, which was first reported by Huffington Post.</p>
<p>"Though marijuana is widely used and, according to HHS, is associated with fewer adverse outcomes than alcohol, it remains in the most restrictive schedule of the CSA. This placement produces a cascade of severe penalties for marijuana users and businesses, including for criminal records, immigration statuses, employment, taxation, health care, public housing, social services, and more," the group wrote.</p>
<h1 class="wp-block-heading"><strong>Issues With The DEA Notwithstanding&#8230;</strong></h1>
<p>While acknowledging the potential for internal <a href="https://www.benzinga.com/markets/cannabis/24/03/37603576/dea-vs-white-house-agency-pushes-back-on-medical-benefits-of-cannabis-weed-stocks-wobble">disagreements within the DEA</a> and the White House, the letter stresses the need for swift action. </p>
<p>"We urge you to promptly remove marijuana from Schedule I of the Controlled Substances Act (CSA). In recent months, we have sent you multiple letters explaining the importance of doing so," they continued.</p>
<h1 class="wp-block-heading"><strong>Rescheduling Is Important, But Full Legalization Is Best</strong></h1>
<p>The letter cited previous correspondence reiterating that while reclassification to Schedule III would be a step forward, the ultimate solution lies in descheduling marijuana altogether.</p>
<p>"The longer marijuana remains scheduled in the CSA, the longer our communities face senselessly severe penalties and the longer the marijuana laws of the majority of U.S. states remain in conflict with federal law. Right now, the Administration has the opportunity to resolve more than 50 years of failed, racially discriminatory marijuana policy," the Democrats wrote.</p>
<p>In addition to praising Biden&#8217;s support for marijuana reform, the letter highlighted the significance of <a href="https://www.benzinga.com/markets/cannabis/24/04/38240431/biden-champions-cannabis-reform-and-pardon-as-election-pressure-mounts-marijuana-takes-center-st">Second Chance Month</a> as an opportunity to rectify the harms caused by marijuana&#8217;s scheduling.</p>
<p>"April 2024 — proclaimed "Second Chance Month" — is a prime opportunity to finally begin remedying the harms of marijuana's scheduling by removing marijuana from Schedule I," the 20 lawmakers said.</p>
<p><em>Photo: Benzinga edit with&nbsp;Billion Photos and Yarygin by Shutterstock</em></p>


Legal

Senators Warren, Fetterman Plus 18 More Dems Tell DEA 'It's Time To Act' On Cannabis Rescheduling

<p><strong>OKB's</strong> (CRYPTO:OKB) price has decreased 3.04% over the past 24 hours to <strong>$53.0</strong>, continuing its downward trend over the past week of -5.0%, moving from $55.65 to its current price. </p>
<p>The chart below compares the price movement and volatility for OKB over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714071755_0.png" alt="price_chart" /></p>
<p>The trading volume for the coin has decreased 32.0% over the past week, while the overall circulating supply of the coin has increased 0.8% to over 60.00 million. This puts its current circulating supply at an estimated 20.0% of its max supply, which is 300.00 million. The current market cap ranking for OKB is #39 at $3.18 billion.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714071755_1.png" alt="supply_and_vol" /></p>
<p><a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Cryptocurrency OKB Decreases More Than 3% Within 24 hours

<p><strong>Uniswap's</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/uni/usd">UNI</a>) price has increased 3.22% over the past 24 hours to <strong>$7.98</strong>. Over the past week, UNI has experienced an uptick of over 11.0%, moving from $7.19 to its current price.  As it stands right now, <strong>the coin's all-time high is $44.92</strong>. </p>
<p>The chart below compares the price movement and volatility for Uniswap over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714071745_0.png" alt="price_chart" /></p>
<p><strong>The trading volume for the coin has increased 1.0%</strong> over the past week while the overall circulating supply of the coin has increased 0.04% to over 753.77 million which makes up an estimated 75.38% of its max supply, which is 1.00 billion. The current market cap ranking for <strong>UNI</strong> is <strong>#23</strong> at <strong>$6.03 billion</strong>.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714071746_1.png" alt="supply_and_vol" /></p>
<p><a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$UNI

Cryptocurrency Uniswap Up More Than 3% In 24 hours

<p>Across the recent three months, 5 analysts have shared their insights on YETI Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YETI#NYSE">YETI</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated YETI Holdings and provided 12-month price targets. The average target is $41.8, accompanied by a high estimate of $48.00 and a low estimate of $38.00. This current average has decreased by 7.62% from the previous average price target of $45.25. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714071692_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive YETI Holdings. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anna Glaessgen</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$38.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Brian McNamara</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$40.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Anna Glaessgen</td>
<td>B. Riley Securities</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$42.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Altobello</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$48.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Jim Duffy</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$41.00</td>
<td>$43.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to YETI Holdings. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of YETI Holdings compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for YETI Holdings's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>To gain a panoramic view of YETI Holdings's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/YETI/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on YETI Holdings analyst ratings.</strong></a></p>
<h2>All You Need to Know About YETI Holdings</h2>
<p>YETI Holdings Inc is a designer, marketer, and distributor of premium products for the outdoor and recreation market sold under the YETI brand. The company offers products including coolers and equipment, drinkware, and other accessories. Its trademark products include YETI Tundra, Hopper, YETI TANK, Rambler, Colster, Rambler among others. The company distributes products through wholesale channels and through direct-to-consumer, or DTC, channels.</p>
<h3>Understanding the Numbers: YETI Holdings's Finances</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Revenue Growth:</strong> YETI Holdings displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately <strong>16.03%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>15.12%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>11.54%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> YETI Holdings's ROA excels beyond industry benchmarks, reaching <strong>6.41%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.24</strong>, YETI Holdings adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


YETI

Demystifying YETI Holdings: Insights From 5 Analyst Reviews

<p>Throughout the last three months, 6 analysts have evaluated Popular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPOP#NASDAQ">BPOP</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Popular and provided 12-month price targets. The average target is $106.83, accompanied by a high estimate of $115.00 and a low estimate of $99.00. This current average has increased by 5.56% from the previous average price target of $101.20. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714071680_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Popular by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$99.00</td>
</tr>
<tr>
<td>Timur Braziler</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Kelly Motta</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Alexander Twerdahl</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Ben Gerlinger</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$107.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$99.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Popular. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Popular compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Popular's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Popular's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BPOP/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Popular analyst ratings.</strong></a></p>
<h2>About Popular</h2>
<p>Popular Inc, based in Puerto Rico, is a financial holding company with four main subsidiaries: Banco Popular de Puerto Rico, a bank in Puerto Rico in terms of assets; Banco Popular North America, its banking operation in the continental United States; Evertec, a data processor; and Popular Financial Holdings, a diversified financial services company. The Corporation's reportable segments consist of Banco Popular de Puerto Rico and Popular U.S.</p>
<h3>Popular's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Popular's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2023, the company experienced a revenue decline of approximately <strong>-1.72%</strong>. This indicates a decrease in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.</p>
<p><strong>Net Margin:</strong> Popular's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>13.99%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Popular's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>1.97%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>0.13%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Popular's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.22</strong>.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


BPOP

Popular Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)

<p>Over the past 24 hours, <strong>TRON's</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/trx/usd">TRX</a>) price has risen 3.3% to <strong>$0.12</strong>. This continues its positive trend over the past week where it has experienced a 7.0% gain, moving from $0.11 to its current price. As it stands right now, <strong>the coin's all-time high is $0.23</strong>. </p>
<p>The chart below compares the price movement and volatility for TRON over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714071675_0.png" alt="price_chart" /></p>
<p>The trading volume for the coin has decreased 0.0% over the past week, while the overall circulating supply of the coin has decreased 0.08% to over 87.57 billion. The current market cap ranking for TRX is #14 at $10.25 billion.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714071675_1.png" alt="supply_and_vol" /></p>
<p><a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$TRX

TRON Up More Than 3% In 24 hours

<p>Deep-pocketed investors have adopted a bearish approach towards Nucor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in NUE usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 12 extraordinary options activities for Nucor. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 25% leaning bullish and 58% bearish. Among these notable options, 5 are puts, totaling $179,870, and 7 are calls, amounting to $361,723.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $160.0 to $200.0 for Nucor over the last 3 months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Nucor's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Nucor's whale trades within a strike price range from $160.0 to $200.0 in the last 30 days. </p>
<h3>Nucor Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714071676_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>NUE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$20.5</td>
<td>$20.1</td>
<td>$20.2</td>
<td>$200.00</td>
<td>$109.1K</td>
<td style="text-align: right;">418</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>NUE</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$30.2</td>
<td>$29.3</td>
<td>$29.8</td>
<td>$180.00</td>
<td>$59.6K</td>
<td style="text-align: right;">101</td>
<td style="text-align: right;">22</td>
</tr>
<tr>
<td>NUE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$2.15</td>
<td>$2.1</td>
<td>$2.15</td>
<td>$177.50</td>
<td>$50.9K</td>
<td style="text-align: right;">96</td>
<td style="text-align: right;">4</td>
</tr>
<tr>
<td>NUE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$16.4</td>
<td>$16.1</td>
<td>$16.2</td>
<td>$170.00</td>
<td>$46.9K</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">30</td>
</tr>
<tr>
<td>NUE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$15.2</td>
<td>$15.0</td>
<td>$15.0</td>
<td>$170.00</td>
<td>$43.5K</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">29</td>
</tr>
</tbody>
</table>
</p>
<h3>About Nucor</h3>
<p>Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products, and raw materials, the steel mills segment derives maximum revenue. The steel mills segment includes carbon and alloy steel in sheet, bars, structural and plate; steel trading businesses; rebar distribution businesses; and Nucor's equity method investments in NuMit and NJSM.</p>
<p>After a thorough review of the options trading surrounding Nucor, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Nucor's Current Market Status</h3>
<ul>
<li>With a trading volume of 928,197, the price of NUE is up by 1.41%, reaching $175.19.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 88 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Nucor</h3>
<p>A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $195.0.</p>
<ul>
<li>An analyst from JP Morgan has decided to maintain their Neutral rating on Nucor, which currently sits at a price target of $195. </li>
<li>An analyst from BMO Capital persists with their Market Perform rating on Nucor, maintaining a target price of $200. </li>
<li>An analyst from JP Morgan persists with their Neutral rating on Nucor, maintaining a target price of $190. </li>
</ul>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Nucor, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Nucor Unusual Options Activity

<p>High-rolling investors have positioned themselves bearish on AutoZone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>), and it's important for retail traders to take note.<br />
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in AZO often signals that someone has privileged information.</p>
<p>Today, Benzinga's options scanner spotted 14 options trades for AutoZone. This is not a typical pattern.</p>
<p>The sentiment among these major traders is split, with 28% bullish and 42% bearish. Among all the options we identified, there was one put, amounting to $27,720, and 13 calls, totaling $572,570.</p>
<h3>Expected Price Movements</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $2600.0 and $3100.0 for AutoZone, spanning the last three months.</p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for AutoZone's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of AutoZone's whale activity within a strike price range from $2600.0 to $3100.0 in the last 30 days. </p>
<h3>AutoZone Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714071670_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>AZO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$131.9</td>
<td>$127.0</td>
<td>$127.0</td>
<td>$2870.00</td>
<td>$127.0K</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">12</td>
</tr>
<tr>
<td>AZO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$230.0</td>
<td>$223.7</td>
<td>$230.0</td>
<td>$3050.00</td>
<td>$46.0K</td>
<td style="text-align: right;">31</td>
<td style="text-align: right;">6</td>
</tr>
<tr>
<td>AZO</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$227.8</td>
<td>$214.3</td>
<td>$220.0</td>
<td>$3050.00</td>
<td>$44.0K</td>
<td style="text-align: right;">31</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>AZO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$221.4</td>
<td>$205.5</td>
<td>$215.0</td>
<td>$3100.00</td>
<td>$43.0K</td>
<td style="text-align: right;">30</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>AZO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$220.0</td>
<td>$205.1</td>
<td>$210.0</td>
<td>$3050.00</td>
<td>$42.0K</td>
<td style="text-align: right;">31</td>
<td style="text-align: right;">2</td>
</tr>
</tbody>
</table>
</p>
<h3>About AutoZone</h3>
<p>AutoZone operates as a leading retailer of aftermarket automotive parts in the United States. The firm operates over 6,300 stores domestically, serving both the do-it-yourself and commercial (do-it-for-me) end markets. Through its vast store footprint and distribution network, AutoZone manages a wide array of stock-keeping units applicable to numerous vehicle makes and models, providing its consumers with ample product availability. The firm drives traffic by providing superior and convenient customer service as AutoZone's team of knowledgeable staff assists consumers with diagnosing a vehicle's problem, selecting the necessary part for replacement, and in some instances, installation. The company also operates internationally, with over 750 stores in Mexico and 100 in Brazil.</p>
<p>In light of the recent options history for AutoZone, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Where Is AutoZone Standing Right Now?</h3>
<ul>
<li>With a trading volume of 135,497, the price of AZO is down by -1.79%, reaching $2934.99.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 26 days from now.</li>
</ul>
<h3>What The Experts Say On AutoZone</h3>
<p>2 market experts have recently issued ratings for this stock, with a consensus target price of $3434.5.</p>
<ul>
<li>Consistent in their evaluation, an analyst from Evercore ISI Group keeps a Outperform rating on AutoZone with a target price of $3346. </li>
<li>Consistent in their evaluation, an analyst from Truist Securities keeps a Buy rating on AutoZone with a target price of $3523. </li>
</ul>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for AutoZone, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


What the Options Market Tells Us About AutoZone

<p>Across the recent three months, 7 analysts have shared their insights on Virtu Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRT#NASDAQ">VIRT</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Virtu Finl and provided 12-month price targets. The average target is $22.0, accompanied by a high estimate of $25.00 and a low estimate of $19.00. Surpassing the previous average price target of $20.50, the current average has increased by 7.32%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714071671_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Virtu Finl. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kenneth Worthington</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$21.50</td>
<td>$20.00</td>
</tr>
<tr>
<td>Craig Siegenthaler</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$25.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Patrick Moley</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$25.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$20.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Christopher Allen</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$22.50</td>
<td>$21.00</td>
</tr>
<tr>
<td>Patrick Moley</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$21.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$19.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Virtu Finl. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Virtu Finl compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Virtu Finl's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Virtu Finl's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/VIRT/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Virtu Finl analyst ratings.</strong></a></p>
<h2>Get to Know Virtu Finl Better</h2>
<p>Virtu Financial Inc is a technology-enabled market maker and liquidity provider to the financial markets. The company's operating segment includes Market Making; and Execution Services. The non-operating segment of the company includes the Corporate segment. The company generates maximum revenue from the market-making segment. The Market Making segment principally consists of market-making in the cash, futures, and options markets across equities, options, fixed income, currencies, and commodities. Geographically, it derives a majority of its revenue from the United States and also has a presence in Ireland and Other Countries.</p>
<h3>Virtu Finl: A Financial Overview</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Virtu Finl's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately <strong>7.68%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> Virtu Finl's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>0.81%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>0.35%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Virtu Finl's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>0.03%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>4.27</strong>, caution is advised due to increased financial risk.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


VIRT

7 Analysts Assess Virtu Finl: What You Need To Know

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>Constellation Energy</strong>.</p>
<p>Looking at options history for Constellation Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>) we detected 15 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 26% of the investors opened trades with bullish expectations and 60% with bearish.</p>
<p>From the overall spotted trades, 7 are puts, for a total amount of $1,161,248 and 8, calls, for a total amount of $342,053.</p>
<h3>Predicted Price Range</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $165.0 to $200.0 for Constellation Energy over the last 3 months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of Constellation Energy stands at 250.0, with a total volume reaching 835.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Constellation Energy, situated within the strike price corridor from $165.0 to $200.0, throughout the last 30 days.</p>
<h3>Constellation Energy Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714071665_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CEG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$5.8</td>
<td>$5.4</td>
<td>$5.75</td>
<td>$165.00</td>
<td>$820.9K</td>
<td>180</td>
<td style="text-align: right;">63</td>
</tr>
<tr>
<td>CEG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$9.1</td>
<td>$8.6</td>
<td>$9.1</td>
<td>$185.00</td>
<td>$96.4K</td>
<td>109</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>CEG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$12.2</td>
<td>$12.0</td>
<td>$12.0</td>
<td>$190.00</td>
<td>$95.5K</td>
<td>118</td>
<td style="text-align: right;">51</td>
</tr>
<tr>
<td>CEG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$8.1</td>
<td>$8.1</td>
<td>$8.1</td>
<td>$195.00</td>
<td>$80.1K</td>
<td>1.0K</td>
<td style="text-align: right;">168</td>
</tr>
<tr>
<td>CEG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$24.7</td>
<td>$24.6</td>
<td>$24.7</td>
<td>$190.00</td>
<td>$74.1K</td>
<td>27</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
</p>
<h3>About Constellation Energy</h3>
<p>Constellation Energy Corp offers energy solutions. It provides clean energy and sustainable solutions to homes, businesses, the public sector, community aggregations, and a range of wholesale customers (such as municipalities, cooperatives, and other strategics). The company offers comprehensive energy solutions and a variety of pricing options for electric, natural gas, and renewable energy products for companies of any size.</p>
<h3>Constellation Energy's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 1,998,918, the CEG's price is up by 1.62%, now at $189.18. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 14 days.</li>
</ul>
<h3>What Analysts Are Saying About Constellation Energy</h3>
<p>In the last month, 1 experts released ratings on this stock with an average target price of $198.0.</p>
<ul>
<li>Maintaining their stance, an analyst from Evercore ISI Group continues to hold a Outperform rating for Constellation Energy, targeting a price of $198. </li>
</ul>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Constellation Energy with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Constellation Energy Unusual Options Activity For April 25

<p>In the preceding three months, 4 analysts have released ratings for Cathay General (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CATY#NASDAQ">CATY</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Cathay General and provided 12-month price targets. The average target is $40.75, accompanied by a high estimate of $44.00 and a low estimate of $38.00. This current average has decreased by 7.39% from the previous average price target of $44.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714071661_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>A comprehensive examination of how financial experts perceive Cathay General is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$38.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Christopher Mcgratty</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$41.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>David Chiaverini</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$44.00</td>
<td>-</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$40.00</td>
<td>$46.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Cathay General. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Cathay General compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Cathay General's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Cathay General's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CATY/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Cathay General analyst ratings.</strong></a></p>
<h2>Discovering Cathay General: A Closer Look</h2>
<p>Cathay General Bancorp is a regional bank predominantly serving the Chinese-American community. The company's policy is to reach out and actively offer services to low-to-moderate income groups in the delineated branch service areas. It predominantly provides services such as checking and deposit, lines of credits, commercial and commercial real estate loans, merchant services and payment processing, treasury management services, international banking and financing services, and other customary banking services to individuals, professionals, and small to medium-sized businesses. Through its Wealth Management unit, the company also offers investment products and services, such as stocks, bonds, mutual funds, insurance, annuities, and advisory services.</p>
<h3>Cathay General: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Cathay General's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2023, the company experienced a revenue decline of approximately <strong>-4.05%</strong>. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> Cathay General's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>40.21%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Cathay General's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>3.07%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Cathay General's ROA excels beyond industry benchmarks, reaching <strong>0.36%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Cathay General's debt-to-equity ratio is below the industry average. With a ratio of <b>0.26</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CATY

What 4 Analyst Ratings Have To Say About Cathay General

<p>In the last three months, 11 analysts have published ratings on Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $425.18, a high estimate of $460.00, and a low estimate of $390.00. Marking an increase of 3.16%, the current average surpasses the previous average price target of $412.17. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714071649_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>A clear picture of Molina Healthcare's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$430.00</td>
<td>$437.00</td>
</tr>
<tr>
<td>Scott Fidel</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$390.00</td>
<td>-</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$410.00</td>
<td>$440.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$406.00</td>
<td>-</td>
</tr>
<tr>
<td>Kevin Fischbeck</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Underperform</td>
<td>$439.00</td>
<td>-</td>
</tr>
<tr>
<td>Kevin Fischbeck</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Underperform</td>
<td>$439.00</td>
<td>-</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$440.00</td>
<td>$420.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$437.00</td>
<td>-</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$460.00</td>
<td>$435.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$420.00</td>
<td>$367.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$406.00</td>
<td>$374.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Molina Healthcare. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Molina Healthcare compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Molina Healthcare's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Molina Healthcare's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MOH/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Molina Healthcare analyst ratings.</strong></a></p>
<h2>All You Need to Know About Molina Healthcare</h2>
<p>Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.</p>
<h3>Key Indicators: Molina Healthcare's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Molina Healthcare showcased positive performance, achieving a revenue growth rate of <strong>10.03%</strong> as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Molina Healthcare's net margin is impressive, surpassing industry averages. With a net margin of <strong>2.39%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Molina Healthcare's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>5.34%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Molina Healthcare's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>1.45%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Molina Healthcare's debt-to-equity ratio surpasses industry norms, standing at <strong>0.57</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Molina Healthcare Stock: A Deep Dive Into Analyst Perspectives (11 Ratings)

<p>Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) has been analyzed by 15 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Humana and provided 12-month price targets. The average target is $371.6, accompanied by a high estimate of $450.00 and a low estimate of $310.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 11.91%. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714071626_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The standing of Humana among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Frank Morgan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$353.00</td>
<td>$415.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$326.00</td>
<td>$334.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$360.00</td>
<td>$391.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$370.00</td>
<td>$415.00</td>
</tr>
<tr>
<td>David Windley</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$381.00</td>
<td>$411.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$391.00</td>
<td>-</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$350.00</td>
<td>$413.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$391.00</td>
<td>-</td>
</tr>
<tr>
<td>Nathan Rich</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$385.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$310.00</td>
<td>$356.00</td>
</tr>
<tr>
<td>Gary Taylor</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$396.00</td>
<td>$427.00</td>
</tr>
<tr>
<td>Kevin Fischbeck</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$342.00</td>
<td>$470.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$356.00</td>
<td>-</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$413.00</td>
<td>$465.00</td>
</tr>
<tr>
<td>Nathan Rich</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$450.00</td>
<td>$515.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Humana. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Humana compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Humana's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Humana's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/HUM/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Humana analyst ratings.</strong></a></p>
<h2>Delving into Humana's Background</h2>
<p>Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.</p>
<h3>Humana: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Humana displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately <strong>17.93%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Humana's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>-2.04%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Humana's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>-3.26%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Humana's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>-1.05%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Humana's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>0.74</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


-

-

-

-

-

-

-

-

-

-

-

-

-

-

Latest News for USCF Midstream Energy Income Fund ETF (ARCA:UMI)

Tuesday, July 25, 2023